Community Bank & Trust Waco Texas grew its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 132.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 2,643 shares of the medical instruments supplier’s stock after acquiring an additional 1,506 shares during the period. Community Bank & Trust Waco Texas’ holdings in Becton Dickinson and were worth $690,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in BDX. Acropolis Investment Management LLC acquired a new position in shares of Becton Dickinson and in the 3rd quarter worth approximately $101,000. Almanack Investment Partners LLC. acquired a new position in shares of Becton Dickinson and in the 2nd quarter worth approximately $105,000. Bartlett & Co. LLC grew its stake in shares of Becton Dickinson and by 2,900.0% in the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after purchasing an additional 435 shares during the last quarter. BDO Wealth Advisors LLC grew its stake in shares of Becton Dickinson and by 361.6% in the 1st quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock worth $125,000 after purchasing an additional 452 shares during the last quarter. Finally, Bridgeworth LLC acquired a new position in shares of Becton Dickinson and in the 2nd quarter worth approximately $131,000. Institutional investors own 92.51% of the company’s stock.
Several equities analysts have recently issued reports on the stock. Citigroup lifted their price objective on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $248.00 price objective on shares of Becton Dickinson and in a research note on Friday, August 3rd. JPMorgan Chase & Co. raised shares of Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price objective on the stock in a research note on Thursday, June 21st. ValuEngine raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Finally, Morgan Stanley lifted their price objective on shares of Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 4th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $253.79.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.05. The business had revenue of $4.28 billion for the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. The firm’s quarterly revenue was up 41.0% compared to the same quarter last year. During the same period last year, the firm posted $2.46 earnings per share. On average, equities research analysts predict that Becton Dickinson and Co will post 11.01 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, September 28th. Stockholders of record on Friday, September 7th were given a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.24%. The ex-dividend date of this dividend was Thursday, September 6th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 31.65%.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Featured Story: How to Invest in Growth Stocks
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.